Cwm, LLC Ultragenyx Pharmaceutical Inc. Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Cwm, LLC holds 21,332 shares of RARE stock, worth $1.03 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

21,332

Previous 221 9552.49%

Holding current value

$1.03 Million

Previous $9,000 13066.67%

% of portfolio

0.01%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$40.21 - $59.36 $848,873 - $1.25 Million	21,111 Added 9552.49%	21,332 $1.19 Million
Q2 2024 Jul 09, 2024	SELL	$37.42 - $51.61 $33,416 - $46,087	-893 Reduced 80.16%	221 $9,000
Q1 2024 Apr 05, 2024	BUY	$43.02 - $53.69 $33,942 - $42,361	789 Added 242.77%	1,114 $52,000
Q4 2023 Feb 01, 2024	BUY	$31.73 - $49.19 $3,299 - $5,115	104 Added 47.06%	325 $16,000
Q3 2023 Oct 11, 2023	BUY	$34.92 - $46.66 $6,669 - $8,912	191 Added 636.67%	221 $8,000
Q2 2023 Aug 03, 2023	BUY	$37.35 - $52.15 $112 - $156	3 Added 11.11%	30 $1,000
Q1 2023 Apr 28, 2023	BUY	$36.99 - $48.71 $184 - $243	5 Added 22.73%	27 $1,000
Q4 2022 Feb 01, 2023	SELL	$33.72 - $46.33 $809 - $1,111	-24 Reduced 52.17%	22 $1,000
Q3 2022 Oct 27, 2022	SELL	$39.96 - $66.14 $5,114 - $8,465	-128 Reduced 73.56%	46 $2,000
Q2 2022 Jul 28, 2022	BUY	$45.8 - $85.4 $6,824 - $12,724	149 Added 596.0%	174 $10,000
Q1 2022 Apr 21, 2022	BUY	$62.2 - $84.4 $1,555 - $2,110	25 New	25 $2,000
Q4 2018 Jan 25, 2019	SELL	$38.89 - $77.3 $116 - $231	-3 Closed	0 $0
Q3 2017 Oct 16, 2017	BUY	$49.79 - $66.32 $149 - $198	3	3 $0

Others Institutions Holding RARE

# of Institutions

326

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.37B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account